• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Thromboembolism in a patient with a mechanical mitral valve during anticoagulation with dabigatran etexilate.
We report a 57-year-old man with a mechanical heart valve who experienced acute upper limb thromboembolism during dabigatran intake. Dabigatran might be inadequate for thromboprophylaxis after mechanical valve replacement. PMID: 24182477 [PubMed - in process]
Source: The Annals of Thoracic Surgery - November 1, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Kuwauchi S, Watanabe S, Abe K, Yamasaki M, Ito J, Kawazoe K Tags: Ann Thorac Surg Source Type: research

A Probable Life-Saving Switch from Apixaban to Phenprocoumon.
Abstract The direct oral anticoagulants (DOAC) dabigatran, rivaroxaban, and apixaban are increasingly prescribed in atrial fibrillation (AF) patients, although dosage in elderly patients, safety in chronic kidney disease, food- and drug-interactions, laboratory tests for monitoring, and antidote are not clarified. In a 78-year-old man with an acute stroke, paroxysmal AF and sick-sinus-syndrome were detected as he received a DDD-pacemaker and 5 mg apixaban/bid. He had a history of hypertension, hypothyroidism, diabetes mellitus, hyperlipidemia, sleep apnea, lumbar discopathy, and nephropathy. Renal function deterio...
Source: The Heart Surgery Forum - October 30, 2015 Category: Cardiovascular & Thoracic Surgery Authors: Stöllberger C, Finsterer J Tags: Heart Surg Forum Source Type: research

Dabigatran etexilate in a vitamin ‐K antagonist non responder patient during Heartware HVAD support
We report a case of a patient supported with a HeartWare left ventricular assist device for idiopathic cardiomyopathy who was resistance to vitamin‐K antagonists three months after implantation. The patient initially started low‐molecular‐weight heparin therapy and then, after the onset of an ischemic stroke, switched to dabigatran etexilate (DE). The patient had progressive recovery of cardiac function for which the device was explanted. No thrombotic or bleeding events occurred during DE therapy.
Source: Journal of Cardiac Surgery - December 31, 2016 Category: Cardiovascular & Thoracic Surgery Authors: Andrea Baronetto, Paolo Centofanti, Matteo Attisani, Massimo Boffini, Davide Ricci, Erika Simonato, Mauro Rinaldi Tags: PERIOPERATIVE MANAGEMENT Source Type: research